Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors

Michelle Isaacs; Katherine T Tonks; Jerry R Greenfield

doi:10.1111/imj.13442

Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors

Intern Med J. 2017 Jun;47(6):701-704. doi: 10.1111/imj.13442.

Authors

Michelle Isaacs¹, Katherine T Tonks^{1

2

3}, Jerry R Greenfield^{1

2

3}

Affiliations

¹ Department of Endocrinology and Diabetes, St Vincent's Hospital, Sydney, New South Wales, Australia.
² Diabetes and Metabolism Division, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
³ Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.

PMID: 28580740
DOI: 10.1111/imj.13442

Abstract

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are an increasingly prescribed class of medication for type 2 diabetes mellitus. Euglycaemic diabetic ketoacidosis (euDKA) has been reported in association with SGLT2i use. Clinicians need to understand how to recognise and treat this complication. We describe three cases of euDKA in patients treated with SGLT2i.

Keywords: diabetes mellitus, type 2; diabetic ketoacidosis; humans; hypoglycaemic agents; sodium-glucose transporter 2.

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Benzhydryl Compounds / adverse effects*
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / diagnosis
Diabetes Mellitus, Type 2 / drug therapy*
Diabetic Ketoacidosis / blood
Diabetic Ketoacidosis / chemically induced*
Diabetic Ketoacidosis / diagnosis
Female
Glucosides / adverse effects*
Humans
Male
Middle Aged
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors*

Substances

Benzhydryl Compounds
Glucosides
SLC5A2 protein, human
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
empagliflozin